Cumulative incidence of MDS-CA (left panel), persistent MDS-CA (middle panel), and clinical MDS/AL (right panel), by protocol. (A) From protocol enrollment, the cumulative incidence of MDS-CA and, to a lesser degree, of clinical disease increased progressively with transition from TT2 to TT3a to TT3b. (B) From first transplantation, the cumulative incidence of MDS-CA and, to a lesser degree, of clinical disease increased progressively with transition from TT2 to TT3a to TT3b. (C) From start of maintenance therapy, the cumulative incidence of MDS-CA and, to a lesser degree, of clinical disease increased progressively with transition from TT2 to TT3a to TT3b.